The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a real-world study
替雷利珠单抗联合每周一次的白蛋白紫杉醇、卡铂和西妥昔单抗作为复发或转移性头颈部鳞状细胞癌一线治疗的疗效和安全性:一项真实世界研究
期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2025.1708410
Ouyang, Zhanyong; Zhang, Linting; Wang, Feng; Chen, Meijing; Cheng, Boran; Yang, Fang; Lai, Wenjuan; Gao, Jing; Wang, Shubin; Tong, Gangling